Ensysce Biosciences, Inc. - Common Stock (ENSC)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- P/B of 1.16 — trading near book value
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 48.1% — good return on equity
- Revenue growing at 134% annually
Ensysce Biosciences, Inc. - Common Stock (ENSC) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $2 million . Key value metrics: P/B ratio 1.16, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Ensysce Biosciences, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, ENSC shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 48.1% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.92.
StockPik's composite Value Score for ENSC is 48/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ENSC shows revenue growing at 134% year-over-year, with earnings growing at 25%.